Cholera Patents (Class 514/837)
-
Patent number: 9834525Abstract: This disclosure relates to small molecule inhibitors of paxillin and paxillin binding, and related compositions and methods of treatment.Type: GrantFiled: February 4, 2015Date of Patent: December 5, 2017Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Charles Ryan Yates, Duane D. Miller, Frank Park, Jordan J. Toutounchian, Vanessa Morales-Tirado, Shivaputra Patil, Jayaprakash Pagadala, Bilal Abou Aleiwi
-
Patent number: 8841286Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.Type: GrantFiled: September 26, 2011Date of Patent: September 23, 2014Assignee: Gilead Sciences, Inc.Inventor: Alan Bruce Montgomery
-
Patent number: 8557301Abstract: Disclosed are oral rehydration compositions with sucrose, sodium, chloride, and citric acid or citrate. The composition further comprises an osmolarity of below 250 mOsm/L, and sodium below 75 meq/L. Further disclosed are methods of treatment using the same.Type: GrantFiled: July 1, 2011Date of Patent: October 15, 2013Assignee: Drip Drop, Inc.Inventor: Eduardo P. Dolhun
-
Patent number: 8349575Abstract: The present invention provides a method and composition for raising an immune response in an animal. The method comprising administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety. The targeting moiety binds to at least one receptor that is upregulated on lymphocytes that home to MAdCAM+ mucosal lymphoid tissues.Type: GrantFiled: February 17, 2011Date of Patent: January 8, 2013Assignee: The Council of the Queensland Institute of Medical Research (QIMR)Inventors: Brent Steven McKenzie, Jefferey Stephen Boyle, Andrew Mark Lew
-
Patent number: 8097430Abstract: The present invention provides a method of raising an immune response in an animal. The method comprises administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety wherein the targeting moiety binds to at least one receptor present in circulatory vessels in Gut Associated Lymphoid Tissue. It is preferred that the targeting moiety binds to Mucosal Addressin Cellular Adhesion Molecule-1.Type: GrantFiled: May 24, 2002Date of Patent: January 17, 2012Assignee: The Council of Queensland Institute of Medical ResearchInventors: Brent McKenzie, Jefferey Boyle, Andrew Lew
-
Patent number: 7214364Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.Type: GrantFiled: July 3, 2003Date of Patent: May 8, 2007Assignee: Corus Pharma, Inc.Inventor: Alan Bruce Montgomery
-
Patent number: 6863904Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.Type: GrantFiled: October 14, 2003Date of Patent: March 8, 2005Assignee: Everett Laboratories, Inc.Inventors: John A. Giordano, Charles Balzer
-
Patent number: 6509024Abstract: The first embodiment of the present invention provides a composition, which includes: an aqueous phase dispersed in an oily phase; wherein the oily phase includes at least one particle of a crosslinked solid organopolysiloxane elastomer having at least one oxyalkylene group, and wherein the aqueous phase includes at least one crosslinked and at least partially neutralized poly(2-acrylamido-2-methylpropanesulphonic acid) polymer. Other embodiments of the present invention provide methods of using the above-identified composition, compositions containing same, and a method of preparing water-in-oil emulsions.Type: GrantFiled: March 21, 2001Date of Patent: January 21, 2003Assignee: L'OrealInventor: Raluca Lorant
-
Patent number: 6503883Abstract: The invention relates to a pharmaceutical preparation, which contains an immunosuppressive active agent in dissolved form in a starch capsule, or hard or soft gelatin capsule which has been coated with one or several polymer films. The invention further relates to a process for the production of the pharmaceutical preparation.Type: GrantFiled: November 28, 2000Date of Patent: January 7, 2003Assignee: Novartis AGInventor: Ulrich Posanski
-
Patent number: 6235787Abstract: Hydrazine derivatives of the formula wherein Y is CO or SO2; R1 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 is lower alkyl, halo-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl or aryl when Y is SO2 and is lower alkyl, halo-lower alkyl, lower alkoxy, lower alkoxycarbonyl, acyl, lower cycloalkyl, aryl, aryl-lower alkyl, aryl-lower alkoxy or NR5R6 when Y is CO; and R3 is hydrogen, lower alkyl optionally substituted by cyano, amino, hydroxy, lower alkoxy, lower alkoxycarbonyl, heterocyclyl or heterocyclylcarbonyl, lower alkenyl, lower alkynyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl or heterocyclyl; or R2 and R3 together form the residue of a 5-, 6- or 7-membered cyclic amide, cyclic imide, cyclic sulphonamide or cyclic urethane group; R4 is lower alkyl, hydroxy-lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a group of the formula X-aryl, X-heteroarType: GrantFiled: June 16, 1998Date of Patent: May 22, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Michael John Broadhurst, William Henry Johnson, Daryl Simon Walter
-
Patent number: 6036953Abstract: Disclosed is a V. cholerae cell containing a DNA encoding a fusion polypeptide that includes a heterologous antigenic polypeptide sequence such as a portion of C. difficile toxin A. The fusion polypeptide also includes one of the following: (i) an E. coli hemolysin A subunit (wich is coexpressed with sequences encoding hemolysin B and D subunits); (ii) a secretion signal sequence and cholera toxin A2 subunit (which is coexpressed with cholera toxin B subunit); or (iii) cholera toxin B subunit.Type: GrantFiled: November 25, 1997Date of Patent: March 14, 2000Assignee: The General Hospital CorporationInventors: Edward T. Ryan, Stephen B. Calderwood
-
Patent number: 5939397Abstract: This invention relates to treatment of cholera and related conditions using oligosaccharide compositions which bind V. cholera toxin and/or one or more serotypes of the organism V. cholera. More specifically, the invention concerns neutralization and removal of V. cholera toxin and/or organisms from the intestinal tract.Type: GrantFiled: March 25, 1998Date of Patent: August 17, 1999Assignee: Synsorb Biotech, Inc.Inventors: Louis D. Heerze, Glen D. Armstrong
-
Patent number: 5827534Abstract: An oral dosage composition for intestinal delivery of a therapeutic agent comprising:(A) a therapeutic agent selected from the group consisting of a drug compound, a biologically active peptide and a vaccine; and(B) an intestinal absorption enhancing effective amount of purified Vibrio cholera zonula occludens toxin.Type: GrantFiled: May 24, 1995Date of Patent: October 27, 1998Assignee: University of Maryland at BaltimoreInventor: Alessio Fasano
-
Patent number: 5817633Abstract: This invention relates to treatment of cholera and related conditions using oligosaccharide compositions which bind V. cholerae toxin and/or one or more serotypes of the organism V. cholerae. More specifically, the invention concerns neutralization and removal of V. cholerae toxin and/or organisms from the intestinal tract.Type: GrantFiled: July 9, 1996Date of Patent: October 6, 1998Assignee: Synsorb Biotech, Inc.Inventors: Louis D. Heerze, Glen D. Armstrong
-
Patent number: 5681862Abstract: A method for controlling the growth of at least one microorganism in an aqueous system susceptible to the growth of said microorganism and in recognized need of said control comprising the step of adding to said aqueous system an ionene polymer in an amount effective to inhibit the growth at least one microorganism selected from Campylobacter spp., Mycobacterium spp., Shigella spp., ribrio spp., Yersinia spp., Entamoeba spp., and poliovirus. The aqueous system is selected from potable water, sewage, and other nonmarine surface water. Methods for controlling the spread of the diseases cholera and polio are also disclosed.Type: GrantFiled: March 5, 1993Date of Patent: October 28, 1997Assignee: Buckman Laboratories International, Inc.Inventors: C. George Hollis, Percy A. Jaquess
-
Patent number: 5665389Abstract: An oral dosage composition for intestinal delivery comprising (A) a biologically active ingredient; and (B) zonula occludens toxin, as well as a method for the use of the same.Type: GrantFiled: February 9, 1996Date of Patent: September 9, 1997Assignee: University of Maryland at BaltimoreInventor: Alessio Fasano
-
Patent number: 5661131Abstract: This invention relates to treatment of cholera and related conditions using oligosaccharide compositions which bind V. cholerae toxin and/or one or more serotypes of the organism V. cholerae. More specifically, the invention concerns neutralization and removal of V. cholerae toxin and/or organisms from the intestinal tract.Type: GrantFiled: June 5, 1995Date of Patent: August 26, 1997Assignee: Synsorb Biotech, Inc.Inventors: Louis D. Heerze, Glen D. Armstrong
-
Patent number: 5435996Abstract: Moisturizing compositions for application to human skin which contain oxyethylene functional organosilanes. When used in skin care applications, these compounds exhibit humectant properties. The oxyethylene functional organosilane is a compound having the formula RSiR'.sub.3 in which R is the radical --O(CH.sub.2 CH.sub.2 O).sub.x R"; R' is an R group or an alkyl radical having one to six carbon atoms; R" is a radical such as hydrogen; an alkyl group of one to six carbon atoms; and an aryl group; and x is an integer having a value of six to thirty.Type: GrantFiled: February 7, 1994Date of Patent: July 25, 1995Assignee: Dow Corning CorporationInventors: David A. Glover, Gary E. LeGrow, Linda M. Madore, Regina M. Malczweski
-
Patent number: 5344820Abstract: Disclosed herein is an infection protectant which is excellent in infection protective effects and is also safe. .kappa.-Casein, a sialic-acid-conjugated protein derived from cow milk, and a glycomacropeptide derived from .kappa.-casein, each of which is useful as an active ingredient in this invention, have been found to be effective for the prevention of adhesion of E. coli on cells and also for the inhibition of transformation of lymphocytes by EBV and also to have strong HI activity against virus. The infection protectant of this invention is hence believed to exhibit marked effects for the prevention of occurrence of infectious diarrhea, for mass protection against spreading of influenza, and also against canceration of lymphocytes. Since the active ingredient of the infection protectant is a substance derived from cow milk, it is free of any problem from the viewpoint of safety. Moreover, it is absolutely tasteless and odorless. It can therefore be added to foods for its application.Type: GrantFiled: May 7, 1992Date of Patent: September 6, 1994Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Shunichi Dosako, Hiroko Kusano, Eiki Deya, Tadashi Idota
-
Patent number: 5100647Abstract: Methods for the therapy of cystic fibrosis, Bartter's syndrome, and secretory diarrheas, and for diuretic treatment, by administering to a patient dodecahydro-7,14-methano-2H,6H-di-pyrido[1,2-a:1',2'-e][1,5]diazocine or a pharmaceutically acceptable derivative thereof are disclosed. The formulations include an aerosol formulation comprising the active ingredient in association with an aerosol propellant.Type: GrantFiled: October 2, 1990Date of Patent: March 31, 1992Assignee: The Trustees of the University of PennsylvaniaInventors: Zalman S. Agus, Ellie Kelepouris, Martin Morad
-
Patent number: 4751064Abstract: A synthetic vaccine against cholera and against heat-labile toxin of E. coli comprising a conjugate of a high-molecular weight carrier with a synthetic polypeptide corresponding to part of the sequence of Subunit B of natural cholera toxin. The sequences of choice are those corresponding to sequences 45 to 64, 50 to 64 and 8 to 20 of Subunit B, or slightly modified sequences, similar to the above.Type: GrantFiled: August 23, 1984Date of Patent: June 14, 1988Assignee: Yeda Research & Development Co., Ltd.Inventors: Michael Sela, Ruth Arnon, Chaim O. Jacob